Correction to Lancet Oncol 2022; 23: 416-27

No authors listed

Published Erratum

No authors listed. Lancet Oncol. 2022 Apr.

. 2022 Apr;23(4):e161.

doi: 10.1016/S1470-2045(22)00131-0.

No abstract available

Erratum for

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Richardson PG, et al. Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10. Lancet Oncol. 2022. PMID: 35151415 Clinical Trial.